{"id":3699,"date":"2024-09-03T22:46:06","date_gmt":"2024-09-03T14:46:06","guid":{"rendered":"http:\/\/oncolab.cn\/index.php\/2024\/09\/03\/%e8%82%bf%e7%98%a4%e5%85%8d%e7%96%ab%e5%ad%a6-%e7%ac%ac38%e7%ab%a0-%e8%a1%80%e6%b6%b2%e8%82%bf%e7%98%a4%e5%85%8d%e7%96%ab%e8%82%bf%e7%98%a4%e5%ad%a6%e7%a0%94%e7%a9%b6%e7%8e%b0%e7%8a%b6%ef%bc%88-2\/"},"modified":"2024-09-03T22:46:06","modified_gmt":"2024-09-03T14:46:06","slug":"%e8%82%bf%e7%98%a4%e5%85%8d%e7%96%ab%e5%ad%a6-%e7%ac%ac38%e7%ab%a0-%e8%a1%80%e6%b6%b2%e8%82%bf%e7%98%a4%e5%85%8d%e7%96%ab%e8%82%bf%e7%98%a4%e5%ad%a6%e7%a0%94%e7%a9%b6%e7%8e%b0%e7%8a%b6%ef%bc%88-2","status":"publish","type":"post","link":"http:\/\/oncolab.cn\/index.php\/2024\/09\/03\/%e8%82%bf%e7%98%a4%e5%85%8d%e7%96%ab%e5%ad%a6-%e7%ac%ac38%e7%ab%a0-%e8%a1%80%e6%b6%b2%e8%82%bf%e7%98%a4%e5%85%8d%e7%96%ab%e8%82%bf%e7%98%a4%e5%ad%a6%e7%a0%94%e7%a9%b6%e7%8e%b0%e7%8a%b6%ef%bc%88-2\/","title":{"rendered":"\u80bf\u7624\u514d\u75ab\u5b66-\u7b2c38\u7ae0 \u8840\u6db2\u80bf\u7624\u514d\u75ab\u80bf\u7624\u5b66\u7814\u7a76\u73b0\u72b6\uff08\u4e0b\uff09"},"content":{"rendered":"
\n
\n
\n
\n
\n

\u4e0a\u671f\u5185\u5bb9\uff1a\u80bf\u7624\u514d\u75ab\u5b66-\u7b2c38\u7ae0 \u8840\u6db2\u80bf\u7624\u514d\u75ab\u80bf\u7624\u5b66\u7814\u7a76\u73b0\u72b6\uff08\u4e0a\uff09<\/span><\/a><\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n


<\/p>\n<\/section>\n<\/section>\n

\n
\n

38.3 \u535a\u7eb3\u5410\u5355\u6297:\u590d\u53d1\/\u96be\u6cbb\u6027ALL\u7684\u65b0\u5e0c\u671b<\/strong><\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u5c3d\u7ba1\u5728\u8fc7\u53bb\u4e09\u5341\u5e74\u4e2d\uff0c\u513f\u79d1\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08ALL\uff09\u7684\u6cbb\u7597\u53d6\u5f97\u4e86\u663e\u8457\u8fdb\u5c55\uff0c\u4f46\u572810-20%\u7684\u75c5\u4f8b\u4e2d\uff0c\u6807\u51c6\u6cbb\u7597\u4ecd\u7136\u4f1a\u5931\u8d25\u3002\u5728\u6210\u4ebaALL\u4e2d\uff0c\u53ea\u6709\u4e00\u534a\u7684\u60a3\u8005\u80fd\u57285\u5e74\u5185\u4fdd\u6301\u65e0\u75c5\u751f\u5b58\uff0c\u590d\u53d1\u540e\u7684\u9884\u540e\u4f9d\u7136\u4e0d\u5bb9\u4e50\u89c2\u3002<\/p>\n

B-ALL\u767d\u8840\u75c5\u7ec6\u80de\u4e0a\u8868\u8fbe\u591a\u79cd\u8868\u9762\u6297\u539f\uff0c\u5982CD19\u3001CD20\u548cCD22\u3002\u8fd9\u4e9b\u53d7\u4f53\u867d\u7136\u5728\u6b63\u5e38B\u7ec6\u80de\u4ece\u524dB\u7ec6\u80de\u665a\u671f\u5230\u6d46\u7ec6\u80de\u5206\u5316\u7684\u8fc7\u7a0b\u4e2d\u90fd\u6709\u8868\u8fbe\uff0c\u4f46\u5728\u9020\u8840\u5e72\u7ec6\u80de\u4e2d\u5e76\u4e0d\u5b58\u5728\u3002\u6b64\u5916\uff0c\u4ece\u5229\u59a5\u6614\u5355\u6297\u7684\u4f7f\u7528\u7ecf\u9a8c\u4e2d\u6211\u4eec\u77e5\u9053\uff0cCD20\u7684\u6291\u5236\u901a\u5e38\u53ea\u4f1a\u5f15\u8d77\u77ed\u6682\u7684B\u7ec6\u80de\u8017\u7aed\uff0c\u5e76\u4e14\u4e0e\u7f55\u89c1\u7684\u514d\u75ab\u6291\u5236\u5e76\u53d1\u75c7\u76f8\u5173\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u65e9\u671f\u4f7f\u7528\u6807\u51c6\u5355\u6297\u8f93\u6ce8\u65b9\u6848\u8fdb\u884c\u7684\u53cc\u7279\u5f02\u6027\u6297\u4f53\uff08BsAb\uff09\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\u4e0d\u4f73\uff0c\u4e14\u8010\u53d7\u6027\u8f83\u5dee\u3002\u7136\u800c\uff0c\u5728\u7315\u7334\u6a21\u578b\u4e2d\u8fdb\u884c\u7684\u521d\u6b65\u7814\u7a76\u63ed\u793a\u4e86\u8fd9\u4e9b\u5206\u5b50\u72ec\u7279\u7684\u836f\u4ee3\u52a8\u529b\u5b66\u7279\u6027\u3002\u4e0e\u5229\u59a5\u6614\u5355\u6297\u7b49\u5355\u514b\u9686\u6297\u4f53\u768421\u5929\u534a\u8870\u671f\u76f8\u6bd4\uff0cBsAb\u7684\u534a\u8870\u671f\u6781\u77ed\uff0c\u4ec5\u4e3a2\u5c0f\u65f6\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u57fa\u4e8e\u8fd9\u4e9b\u4e34\u5e8a\u524d\u836f\u4ee3\u52a8\u529b\u5b66\u6570\u636e\uff0c\u7814\u7a76\u8005\u4eec\u6539\u7528\u8ff7\u4f60\u6cf5\u8fdb\u884c\u8fde\u7eed28\u5929\u7684blinatumomab\u8f93\u6ce8\uff0c\u4ee5\u7ef4\u6301\u836f\u7269\u7684\u7a33\u5b9a\u6d53\u5ea6\uff0c\u4ece\u800c\u63d0\u9ad8\u7597\u6548\u548c\u8010\u53d7\u6027\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u5728\u590d\u53d1\/\u96be\u6cbb\u6027\u6210\u4eba\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08ALL\uff09\u60a3\u8005\u4e2d\uff0c\u4e24\u9879II\u671f\u8bd5\u9a8c\u7684\u6210\u529f\u7ed3\u679c\u4fc3\u4f7fFDA\u4e8e2014\u5e7412\u6708\u6279\u51c6\u4e86Blinatumomab\uff0c\u968f\u540eEMA\u4e5f\u57282015\u5e7411\u6708\u7ed9\u4e88\u6279\u51c6\u3002\u5728MT103-206\u8bd5\u9a8c\u4e2d\uff0c36\u540d\u60a3\u8005\u8fde\u7eed\u63a5\u53d7Blinatumomab\u6cbb\u7597\uff0c\u7ed3\u679c\u663e\u793a69%\u7684\u60a3\u8005\u8fbe\u5230\u4e86\u5b8c\u5168\u7f13\u89e3\uff08CR\uff09\u6216\u8840\u6db2\u7cfb\u7edf\u90e8\u5206\u6062\u590d\u7684\u5b8c\u5168\u7f13\u89e3\uff08CRh\uff09\u3002\u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0c\u5728\u65e9\u671f\u7684I\u671f\u8bd5\u9a8c\u4e2d\uff0c\u4e2d\u67a2\u795e\u7ecf\u7cfb\u7edf\u4e0d\u826f\u4e8b\u4ef6\u88ab\u8ba4\u4e3a\u662f\u6700\u663e\u8457\u7684\u5e76\u53d1\u75c7\uff0c\u5bfc\u81f4\u90e8\u5206\u60a3\u8005\u4e0d\u5f97\u4e0d\u4e2d\u6b62\u6cbb\u7597\u3002<\/p>\n

\u5728\u4e00\u4e2a\u5927\u89c4\u6a21\u7684\u9a8c\u8bc1\u6027II\u671f\u8bd5\u9a8c\u4e2d\uff0c\u8fd9\u4e9b\u524d\u6240\u672a\u6709\u7684\u7ed3\u679c\u5728189\u540d\u60a3\u8005\u4e2d\u5f97\u5230\u4e86\u8fdb\u4e00\u6b65\u9a8c\u8bc1\u3002\u65e0\u8bba\u60a3\u8005\u662f\u5426\u63a5\u53d7\u8fc7\u540c\u79cd\u5f02\u4f53\u9020\u8840\u5e72\u7ec6\u80de\u79fb\u690d\uff0cCR\u6216CRh\u7684\u53d1\u751f\u7387\u76f8\u4f3c\uff0c\u5206\u522b\u4e3a42%\u548c45%\u3002\u7279\u522b\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u572852\u540d\u8fbe\u5230CR\u6216CRh\u7684\u60a3\u8005\u4e2d\uff0c\u670932\u540d\u60a3\u8005\u968f\u540e\u63a5\u53d7\u4e86\u540c\u79cd\u5f02\u4f53\u9020\u8840\u5e72\u7ec6\u80de\u79fb\u690d\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u6700\u8fd1\uff0cIII\u671fTOWER\u8bd5\u9a8c\u8fdb\u4e00\u6b65\u786e\u8ba4\u4e86Blinatumomab\u5728\u590d\u53d1\/\u96be\u6cbb\u6027ALL\u6210\u4eba\u60a3\u8005\u4e2d\u76f8\u8f83\u4e8e\u6807\u51c6\u6cbb\u7597\u7684\u4f18\u52bf\u3002\u5728\u7eb3\u5165\u7684405\u540d\u60a3\u8005\u4e2d\uff0cBlinatumomab\u7ec4\u7684\u4e2d\u4f4d\u603b\u751f\u5b58\u671f\uff08OS\uff09\u4e3a7.7\u4e2a\u6708\uff0c\u800c\u5316\u7597\u7ec4\u4ec5\u4e3a4.0\u4e2a\u6708\u3002Blinatumomab\u6cbb\u7597\u8fd8\u5bfc\u81f4\u4e86\u66f4\u9ad8\u7684\u5b8c\u5168\u7f13\u89e3\u7387\uff0834% vs 16%\uff0cp = 0.01\uff09\u3002\u5728\u6bd2\u6027\u65b9\u9762\uff0c\u7814\u7a76\u663e\u793a\u4e24\u7ec4\u4e2d3\u7ea7\u4e0d\u826f\u4e8b\u4ef6\u7684\u53d1\u751f\u7387\u76f8\u5f53\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u5728\u513f\u7ae5\u590d\u53d1\/\u96be\u6cbb\u6027ALL\u4e2d\uff0cArend von Stackelberg\u53d1\u8868\u4e86\u4e00\u9879\u5305\u62ec90\u591a\u540d\u513f\u7ae5\u7684I\/II\u671f\u7814\u7a76\u3002\u5728\u63a5\u53d7\u6700\u4f73\u5242\u91cf\u6cbb\u7597\u768470\u540d\u60a3\u8005\u4e2d\uff0c39%\u8fbe\u5230\u4e86\u5b8c\u5168\u7f13\u89e3\uff0c52%\u8fbe\u5230\u4e86\u6700\u5c0f\u6b8b\u7559\u75c5\u7076\u7684\u5b8c\u5168\u7f13\u89e3\u3002\u57fa\u4e8e\u4e24\u5e74\u7684\u968f\u8bbf\u6570\u636e\uff0c\u4e2d\u4f4dOS\u4e3a7.5\u4e2a\u6708\uff0c\u8d85\u8fc720%\u7684\u60a3\u8005\u5728\u968f\u8bbf\u671f\u7ed3\u675f\u65f6\u4ecd\u7136\u5b58\u6d3b\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n

\u5b89\u5168\u6027\u6982\u51b5<\/strong><\/p>\n<\/section>\n

\n
\n
\n

PD-1\/PD-L1\u8f74\u7531\u7a0b\u5e8f\u6027\u7ec6\u80de\u6b7b\u4ea1\u86cb\u767d1\uff08PD-1\uff09\u53ca\u5176\u914d\u4f53\uff08PD-L1\u548cPD-L2\uff09\u7ec4\u6210\uff0c\u662f\u7ef4\u6301\u5916\u5468\u514d\u75ab\u8010\u53d7\u7684\u91cd\u8981\u751f\u7406\u673a\u5236\u4e4b\u4e00\u3002\u5b83\u5728\u63a7\u5236\u7ec6\u80de\u6bd2\u6027T\u7ec6\u80de\u53cd\u5e94\u7684\u5f3a\u5ea6\u65b9\u9762\u8d77\u5173\u952e\u4f5c\u7528\uff0c\u5e76\u4e14\u4e0e\u8bb8\u591a\u5176\u4ed6\u6291\u5236\u6027\u53d7\u4f53\u9014\u5f84\u4e0d\u540c\uff0cPD-1\/PD-L1\u8f74\u5728\u51e0\u4e4e\u6240\u6709\u7c7b\u578b\u7684\u708e\u75c7\u6761\u4ef6\u4e0b\u90fd\u6709\u63cf\u8ff0\u3002PD-1\u4e3b\u8981\u5728\u6d3b\u5316\u7684T\u7ec6\u80de\u548cB\u7ec6\u80de\u4e0a\u8868\u8fbe\uff0cT\u7ec6\u80de\u4e0a\u7684PD-1\u8868\u8fbe\u662f\u7531T\u7ec6\u80de\u53d7\u4f53\uff08TCR\uff09\u4f9d\u8d56\u7684\u6fc0\u6d3b\u6240\u8bf1\u5bfc\uff0c\u5c3d\u7ba1\u5176\u8868\u8fbe\u6c34\u5e73\u548c\u65f6\u95f4\u7a97\u53d6\u51b3\u4e8e\u523a\u6fc0\u7684\u5f3a\u5ea6\u548c\u6301\u7eed\u6027\u3002PD-L1\u548cPD-L2\u901a\u5e38\u7531\u67d0\u4e9b\u5de8\u566c\u7ec6\u80de\u4e9a\u7fa4\u8868\u8fbe\uff0c\u4f46\u5728\u591a\u79cd\u9020\u8840\u7ec6\u80de\u548c\u975e\u9020\u8840\u7ec6\u80de\u4e2d\uff0c\u4e5f\u53ef\u4ee5\u88ab\u5404\u79cd\u708e\u75c7\u7ec6\u80de\u56e0\u5b50\u8bf1\u5bfc\u8868\u8fbe\u3002PD-1\/PD-L1\u8f74\u901a\u8fc7\u6291\u5236T\u7ec6\u80de\u7684\u6838\u5fc3\u529f\u80fd\uff08\u5982\u7ec6\u80de\u56e0\u5b50\u4ea7\u751f\u3001\u589e\u6b96\u548c\u7ec6\u80de\u6bd2\u6027\u9897\u7c92\u5f62\u6210\uff09\u6765\u8c03\u8282\u514d\u75ab\u53cd\u5e94\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u5728CAR-T\u7ec6\u80de\u7597\u6cd5\u7684\u65e9\u671f\u8bd5\u9a8c\u4e2d\uff0c\u6709\u62a5\u544a\u663e\u793a\u51fa\u73b0\u4e86\u5371\u53ca\u751f\u547d\u7684\u7ec6\u80de\u56e0\u5b50\u91ca\u653e\u7efc\u5408\u5f81\uff08CRS\uff09\uff0c\u9700\u8981\u4f7f\u7528IL-6\u6291\u5236\u5242\u6258\u73e0\u5355\u6297\uff08tocilizumab\uff09\u8fdb\u884c\u6cbb\u7597\u3002\u4e3a\u4e86\u9884\u9632\u4e25\u91cd\u7684CRS\uff0c\u7279\u522b\u662f\u5728\u7ec6\u80de\u8ba1\u6570\u8d85\u8fc715 \u00d7 109<\/sup>\/L\u7684\u60a3\u8005\u4e2d\uff0c\u5efa\u8bae\u5728\u6cbb\u7597\u524d\u9884\u5148\u4f7f\u7528\u5730\u585e\u7c73\u677e\u3002Blinatumomab\u6cbb\u7597\u4e2d\uff0c\u795e\u7ecf\u7cfb\u7edf\u4e8b\u4ef6\u88ab\u62a5\u544a\u4e3a\u6700\u5177\u6311\u6218\u6027\u548c\u610f\u60f3\u4e0d\u5230\u7684\u6bd2\u6027\u53cd\u5e94\uff0c\u5305\u62ec\u766b\u75eb\u53d1\u4f5c\u3001\u5931\u795e\u53d1\u4f5c\u548c\u610f\u8bc6\u6a21\u7cca\u7b49\u75c7\u72b6\u3002\u5c3d\u7ba1\u6f5c\u5728\u673a\u5236\u5c1a\u4e0d\u5b8c\u5168\u6e05\u695a\uff0c\u4f46\u8fd9\u4e9b\u75c7\u72b6\u53ef\u80fd\u4e0e\u4e2d\u67a2\u795e\u7ecf\u7cfb\u7edf\u77ed\u6682\u6027\u795e\u7ecf\u708e\u75c7\u7684\u523a\u6fc0\u6709\u5173\u3002\u6d3b\u5316\u7684T\u7ec6\u80de\u53ef\u4ee5\u7a7f\u8fc7\u8840\u8111\u5c4f\u969c\uff0c\u5f15\u53d1\u6bd2\u6027\u708e\u75c7\u53cd\u5e94\u3002\u4e3a\u6b64\uff0c\u53d1\u5e03\u4e86\u76f8\u5173\u6307\u5357\uff0c\u4ee5\u5e2e\u52a9\u9884\u9632\u548c\u7ba1\u7406\u8fd9\u4e9b\u795e\u7ecf\u6bd2\u6027\u53cd\u5e94\uff0c\u5efa\u8bae\u91c7\u7528\u5730\u585e\u7c73\u677e\u9884\u9632\u5e76\u6839\u636e\u9700\u8981\u8c03\u6574\u5242\u91cf\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n


<\/p>\n<\/section>\n<\/section>\n

\n
\n

38.4 BiTe\u5728\u975eALL\u8840\u6db2\u7cfb\u7edf\u6076\u6027\u80bf\u7624\u4e2d\u7684\u5e94\u7528<\/strong><\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

BiTe\u7597\u6548\u7684\u6982\u5ff5\u5df2\u5728\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08ALL\uff09\u4e2d\u5f97\u5230\u9a8c\u8bc1\uff0c\u7c7b\u4f3c\u7684\u7269\u8d28\u6b63\u5728\u6d4b\u8bd5\u5176\u4ed6\u9002\u5e94\u75c7\uff1a<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

1. AMG330\uff1a\u8fd9\u662f\u4e00\u4e2a\u9776\u5411CD3\/CD33\u7684\u53cc\u7279\u5f02\u6027\u6297\u4f53\uff0c\u5728\u6025\u6027\u9ad3\u6027\u767d\u8840\u75c5\uff08AML\uff09\u4e2d\u7684\u4e34\u5e8a\u524d\u7814\u7a76\u663e\u793a\uff0c\u9776\u5411CD33\u53ef\u4ee5\u6709\u6548\u5730\u52df\u96c6\u548c\u6269\u589eT\u7ec6\u80de\u3002\u76ee\u524d\uff0cAMG330\u6b63\u5728\u8fdb\u884cI\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff08NCT02520427\uff09\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

2. \u5e03\u5229\u7eb3\u5355\u6297\uff1a\u572821\u4f8b\u7ecf\u8fc7\u91cd\u5ea6\u9884\u5904\u7406\u7684\u5f25\u6f2b\u6027\u5927B\u7ec6\u80de\u6dcb\u5df4\u7624\uff08DLBCL\uff09\u60a3\u8005\u4e2d\uff0c\u5e03\u5229\u7eb3\u5355\u6297\u663e\u793a\u51fa\u4e00\u5b9a\u7684\u7597\u6548\u3002\u5728\u4e00\u4e2a\u6cbb\u7597\u5468\u671f\u540e\uff0c\u603b\u6709\u6548\u7387\u4e3a43%\uff0c\u5176\u4e2d19%\u7684\u60a3\u8005\u8fbe\u5230\u4e86\u5b8c\u5168\u7f13\u89e3\uff08CR\uff09\u3002\u8fdb\u4e00\u6b65\u7684\u7814\u7a76\u6b63\u5728\u8fdb\u884c\u4e2d\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

3. \u591a\u53d1\u6027\u9aa8\u9ad3\u7624\uff1a\u9488\u5bf9\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u7684BiTe\u7597\u6cd5\u6b63\u5728I\u671f\u4e34\u5e8a\u524d\u7814\u7a76\u4e2d\u8fdb\u884c\uff0c\u5176\u4e2d\u5305\u62ec\u9776\u5411B\u7ec6\u80de\u8c31\u7cfb\u4e2d\u7279\u5b9a\u8868\u4f4d\u7684\u5316\u5408\u7269\uff0c\u5982BCMA\u8de8\u819c\u6fc0\u6d3b\u5242\u548c\u9499\u8c03\u8282\u5242\uff0c\u4ec5\u5728B\u7ec6\u80de\u6216We-1\u4e0a\u8868\u8fbe\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

Blinatumomab\u4f5c\u4e3a\u4e00\u79cd\u514d\u75ab\u8c03\u8282\u836f\u7269\uff0c\u5177\u6709\u91cd\u8981\u7684\u6cbb\u7597\u4ef7\u503c\u3002\u7136\u800c\uff0c\u5c3d\u7ba1\u8fd9\u4e9b\u836f\u7269\u5728\u590d\u53d1\/\u96be\u6cbb\u6027ALL\u60a3\u8005\u4e2d\u663e\u793a\u51fa\u826f\u597d\u7684\u7597\u6548\uff0c\u8bb8\u591a\u60a3\u8005\u4ec5\u83b7\u5f97\u4e86\u77ed\u6682\u7684\u7f13\u89e3\uff0c\u8fd9\u4e9b\u836f\u7269\u901a\u5e38\u4ecd\u88ab\u7528\u4f5c\u540c\u79cd\u5f02\u4f53\u9020\u8840\u5e72\u7ec6\u80de\u79fb\u690d\u7684\u6865\u6881\u3002\u4e3a\u63d0\u9ad8\u6cbb\u7597\u6548\u679c\uff0c\u4e34\u5e8a\u8bd5\u9a8c\u6b63\u5728\u63a2\u7d22\u5728\u65e9\u671f\u60a3\u8005\u4e2d\u4f7f\u7528BiTe\uff0c\u5e76\u5c06\u5176\u4e0e\u5176\u4ed6\u514d\u75ab\u6cbb\u7597\u836f\u7269\u8054\u5408\u4f7f\u7528\u3002\u8fd9\u4e9b\u65b0\u7b56\u7565\u6709\u671b\u63d0\u9ad8\u6297\u764c\u6548\u679c\u548c\u6cbb\u6108\u7387\uff0c\u53ef\u80fd\u4f1a\u6539\u53d8\u6211\u4eec\u5bf9\u8840\u6db2\u7cfb\u7edf\u6076\u6027\u80bf\u7624\u7684\u6cbb\u7597\u65b9\u5f0f\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n


<\/p>\n<\/section>\n<\/section>\n

\n
\n

38.5 \u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242(\u6216\u6fc0\u6d3b\u5242)<\/strong><\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

T\u7ec6\u80de\u8870\u7aed\u5bfc\u81f4\u7684\u514d\u75ab\u53cd\u5e94\u7f3a\u9677\u662f\u8bb8\u591a\u7c7b\u578b\u764c\u75c7\u514d\u75ab\u9003\u9038\u7684\u5171\u540c\u7279\u5f81\uff0c\u8fd9\u662f\u672c\u4e66\u5c06\u6df1\u5165\u63a2\u8ba8\u7684\u4e3b\u9898\u3002\u963b\u65ad\u6291\u5236\u6027\u53d7\u4f53CTLA-4\u548cPD-1\u7684\u4e34\u5e8a\u8bd5\u9a8c\u5728\u5b9e\u4f53\u80bf\u7624\u4e2d\u53d6\u5f97\u4e86\u524d\u6240\u672a\u6709\u7684\u6210\u529f\uff0c\u8bc1\u660e\u4e86\u8fd9\u79cd\u6cbb\u7597\u65b9\u6cd5\u7684\u5de8\u5927\u6f5c\u529b\u3002\u5728\u672c\u8282\u4e2d\uff0c\u6211\u4eec\u5c06\u56de\u987e\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\uff08ICB\uff09\u5728\u8840\u6db2\u7cfb\u7edf\u6076\u6027\u80bf\u7624\u4e2d\u6700\u91cd\u8981\u7684\u4e34\u5e8a\u8bd5\u9a8c\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u6297PD-1\u963b\u65ad\u5728\u7ecf\u5178\u970d\u5947\u91d1\u6dcb\u5df4\u7624\uff08cHL\uff09\u4e2d\u7684\u9a8c\u8bc1<\/strong><\/p>\n

\u7ecf\u5178\u970d\u5947\u91d1\u6dcb\u5df4\u7624\uff08cHL\uff09\u662f\u6700\u65e9\u5c1d\u8bd5\u514d\u75ab\u68c0\u67e5\u70b9\u963b\u65ad\u7684\u8840\u6db2\u7cfb\u7edf\u6076\u6027\u80bf\u7624\u4e4b\u4e00\uff0c\u56e0\u4e3a\u5b83\u63d0\u4f9b\u4e86\u4e00\u4e2a\u72ec\u7279\u7684\u6a21\u578b\u6765\u7814\u7a76PD-1\/PD-L1\u8f74\u7684\u6291\u5236\u6548\u679c\u3002\u67d3\u8272\u4f539p24.1\u4f4d\u70b9\uff08\u5305\u62ecPD-L1\u3001PD-L2\u548cJAK2\uff09\u7684\u53cd\u590d\u6269\u589e\u6216EBV\u611f\u67d3\uff0c\u90fd\u4f1a\u5bfc\u81f4Hodgkin\u548cReed-Sternberg\u7ec6\u80de\u8868\u9762PD-L1\u548cPD-L2\u7684\u9ad8\u8868\u8fbe\u3002<\/p>\n

Nivolumab\u662f\u4e00\u79cd\u9776\u5411PD-1\u7684\u5168\u4ebaIgG4\u5355\u514b\u9686\u6297\u4f53\u3002\u572823\u4f8b\u590d\u53d1\/\u96be\u6cbb\u6027cHL\u60a3\u8005\u4e2d\u8fdb\u884c\u7684I\u671f\u5173\u952e\u8bd5\u9a8c\u663e\u793a\u4e86\u663e\u8457\u7684\u4e34\u5e8a\u6210\u529f\uff0c\u5e76\u56e0\u6b64\u4e8e2016\u5e74\u83b7\u5f97\u6279\u51c6(Table 38.1<\/span>)\u3002Nivolumab\u7684\u5b89\u5168\u6027\u826f\u597d\uff0c\u5728\u7ecf\u8fc7\u5927\u91cf\u9884\u5904\u7406\u7684\u60a3\u8005\u4e2d\u663e\u793a\u51fa\u4ee4\u4eba\u5370\u8c61\u6df1\u523b\u7684\u7597\u6548\uff0c\u5ba2\u89c2\u7f13\u89e3\u7387\u8fbe\u5230\u4e8687%\uff0820\/23\uff09\uff0c\u5176\u4e2d17%\u4e3a\u5b8c\u5168\u7f13\u89e3\uff0c70%\u4e3a\u90e8\u5206\u7f13\u89e3\uff0c24\u5468\u65e0\u8fdb\u5c55\u751f\u5b58\u7387\uff08PFS\uff09\u4e3a86%\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
<\/section>\n<\/section>\n
\n
\n
\n


<\/p>\n<\/section>\n<\/section>\n

\n
\n

Table 38.1<\/span> <\/span>\u603b\u7ed3\u4e86\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\u5728\u8840\u6db2\u7cfb\u7edf\u6076\u6027\u80bf\u7624\u4e2d\u7684\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u8be5\u8bd5\u9a8c\u5728\u5931\u8d25\u540e\u62db\u52df\u4e8680\u540d\u60a3\u8005\uff0c\u8fd9\u4e9b\u7ed3\u679c\u5df2\u5728\u4e00\u9879\u5df2\u53d1\u8868\u7684II\u671f\u8bd5\u9a8c\u4e2d\u5f97\u5230\u9a8c\u8bc1\u3002\u8be5\u8bd5\u9a8c\u62db\u52df\u4e8680\u4f8b\u81ea\u4f53\u5e72\u7ec6\u80de\u79fb\u690d\uff08SCT\uff09\u548cBrentuximab Vedotin\uff08BV\uff09\u6cbb\u7597\u5747\u5931\u8d25\u7684\u60a3\u8005\u3002\u53e6\u4e00\u79cd\u6297PD-1\u5355\u6297Pembrolizumab\u5728Ib\u671fKEYNOTE-013\u8bd5\u9a8c\u4e2d\u4e5f\u663e\u793a\u51fa\u7c7b\u4f3c\u7684\u7597\u6548\uff0c\u4f46\u5176\u603b\u4f53\u7f13\u89e3\u7387\uff08ORR\uff09\u4e3a65%\uff0c\u7565\u4f4e\u4e8eNivolumab\u3002<\/p>\n

\u5728\u540c\u79cd\u5f02\u4f53SCT\u5931\u8d25\u540e\uff0cNivolumab\u5728cHL\u4e2d\u7684\u5e94\u7528\u663e\u793a\u51fa\u4e00\u5b9a\u7684\u7597\u6548\uff0c\u5c3d\u7ba1\u5b58\u5728\u5f15\u53d1\u6025\u6027\u79fb\u690d\u7269\u6297\u5bbf\u4e3b\u75c5\uff08GVHD\uff09\u7684\u98ce\u9669\u3002\u7279\u522b\u662f\uff0c\u5bf9\u4e8e\u5728\u540c\u79cd\u5f02\u4f53SCT\u524d\u63a5\u53d7Nivolumab\u6cbb\u7597\u7684\u60a3\u8005\uff0c\u65e9\u671f\u4e25\u91cd\u79fb\u690d\u76f8\u5173\u5e76\u53d1\u75c7\u7684\u53d1\u751f\u7387\u9ad8\u4e8e\u9884\u671f\uff0c\u5305\u62ec\u51e0\u4f8b\u81f4\u547d\u7684\u6025\u6027GVHD\u3002\u8fd9\u4e00\u73b0\u8c61\u503c\u5f97\u8fdb\u4e00\u6b65\u7814\u7a76\u3002<\/p>\n

\u8fc4\u4eca\u4e3a\u6b62\uff0c\u53ea\u8981PD-1\u6291\u5236\u5242\u5bf9\u60a3\u8005\u4ecd\u6709\u76ca\u5904\uff0c\u533b\u751f\u901a\u5e38\u4f1a\u7ee7\u7eed\u5f00\u5904\u65b9\u3002\u5728\u9ed1\u8272\u7d20\u7624\u7684\u6cbb\u7597\u4e2d\uff0c\u4e00\u4e9b\u60a3\u8005\u5df2\u4f7f\u7528PD-1\u6291\u5236\u5242\u957f\u8fbe\u4e24\u5e74\u4e4b\u4e45\u3002\u7136\u800c\uff0c\u5bf9\u4e8e\u54cd\u5e94\u6cbb\u7597\u7684\u60a3\u8005\u6765\u8bf4\uff0cPD-1\u6291\u5236\u5242\u7684\u6700\u4f73\u6cbb\u7597\u6301\u7eed\u65f6\u95f4\u4ecd\u7136\u662f\u4e00\u4e2a\u60ac\u800c\u672a\u51b3\u7684\u95ee\u9898\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n


<\/p>\n<\/section>\n<\/section>\n

\n
\n

38.6 \u5176\u4ed6\u8840\u6db2\u7cfb\u7edf\u6076\u6027\u80bf\u7624\u4e2d\u7684\u68c0\u67e5\u70b9\u963b\u65ad\u7597\u6cd5<\/strong><\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u6211\u4eec\u80fd\u5426\u671f\u671b\u6297PD-1\u7597\u6cd5\u5728\u7ecf\u5178\u970d\u5947\u91d1\u6dcb\u5df4\u7624\uff08cHL\uff09\u4e4b\u5916\u7684\u5176\u4ed6\u8840\u6db2\u7cfb\u7edf\u6076\u6027\u80bf\u7624\u4e2d\u4e5f\u53d6\u5f97\u6210\u529f\uff1f\u65e9\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u521d\u6b65\u7ed3\u679c\u663e\u793a\uff0c\u5355\u836f\u963b\u65adPD-1\u6216CTLA-4\u5728\u8fd9\u4e9b\u75be\u75c5\u4e2d\u7684\u7597\u6548\u8f83\u4f4e\uff0c\u539f\u56e0\u5c1a\u4e0d\u660e\u786e\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n

38.6.1 \u975e\u970d\u5947\u91d1\u6dcb\u5df4\u7624(NHL)<\/p>\n<\/section>\n

\n
\n
\n

\u5173\u4e8e\u68c0\u67e5\u70b9\u963b\u65ad\u6cbb\u7597NHL\u7684\u9996\u4e2a\u7814\u7a76\u662f\u4e00\u9879\u4f7f\u7528\u6297CTLA-4\u5355\u6297Ipilimumab\u7684I\u671f\u8bd5\u9a8c\uff0c\u5176\u603b\u4f53\u7f13\u89e3\u7387\uff08ORR\uff09\u4ec5\u4e3a11%\uff0c\u4ee4\u4eba\u5931\u671b\u3002\u7136\u800c\uff0c\u6709\u4e00\u540d\u5f25\u6f2b\u6027\u5927B\u7ec6\u80de\u6dcb\u5df4\u7624\uff08DLBCL\uff09\u60a3\u8005\u83b7\u5f97\u4e86\u8d85\u8fc731\u4e2a\u6708\u7684\u5b8c\u5168\u7f13\u89e3\uff0c\u53e6\u4e00\u540d\u6ee4\u6ce1\u6027\u6dcb\u5df4\u7624\uff08FL\uff09\u60a3\u8005\u7684\u90e8\u5206\u7f13\u89e3\u6301\u7eed\u4e8619\u4e2a\u6708\uff0c\u8fd9\u8868\u660e\u5373\u4f7f\u5728\u4fb5\u88ad\u6027\u75be\u75c5\u4e2d\uff0c\u68c0\u67e5\u70b9\u963b\u65ad\u53ef\u80fd\u4e5f\u5177\u6709\u6cbb\u7597\u6f5c\u529b\u3002<\/p>\n

\u57fa\u4e8e\u4e00\u9879I\u671f\u7814\u7a76\u7684\u7ed3\u679c\uff0c\u7814\u7a76\u8005\u572866\u540d\u9ad8\u98ce\u9669DLBCL\u6216\u539f\u53d1\u6027\u7eb5\u9694B\u7ec6\u80de\u6dcb\u5df4\u7624\uff08PMBCL\uff09\u60a3\u8005\u81ea\u4f53\u5e72\u7ec6\u80de\u79fb\u690d\uff08SCT\uff09\u540e\uff0c\u8bd5\u9a8c\u4e86\u4eba\u6e90\u5316\u6297PD-1\u5355\u6297Pidilizumab\uff0c\u4ee5\u9a8c\u8bc1PD-1\u963b\u65ad\u80fd\u5426\u5e2e\u52a9\u6839\u9664\u6b8b\u7559\u75be\u75c5\u5e76\u6539\u5584\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\u7684\u5047\u8bbe\u3002\u7ed3\u679c\u663e\u793a\uff0c16\u4e2a\u6708\u65f6\u7684PFS\u4e3a72%\u3002\u6709\u8da3\u7684\u662f\uff0cPidilizumab\u5728\u79fb\u690d\u540e\u6709\u53ef\u6d4b\u91cf\u75be\u75c5\u7684\u60a3\u8005\u4e2d\u5bfc\u81f434%\u7684\u660e\u663e\u5b8c\u5168\u7f13\u89e3\u3002\u6b64\u5916\uff0cPET\u626b\u63cf\u9633\u6027\u7684\u60a3\u8005\u572816\u4e2a\u6708\u65f6\u7684PFS\u4e3a70%\uff0c\u8fd9\u4e00\u7ed3\u679c\u5bf9\u4e8e\u8fd9\u4e2a\u975e\u5e38\u9ad8\u98ce\u9669\u7684\u60a3\u8005\u7fa4\u4f53\u6765\u8bf4\u662f\u76f8\u5f53\u6709\u5229\u7684\u3002<\/p>\n

\u5728\u53e6\u4e00\u4e2a\u7814\u7a76\u4e2d\uff0cPidilizumab\u8054\u5408\u5229\u59a5\u6614\u5355\u6297\u6cbb\u7597\u590d\u53d1\u6027\u5229\u59a5\u6614\u5355\u6297\u654f\u611fFL\u7684ORR\u548cCR\u5206\u522b\u4e3a60%\u548c52%(Table 38.1<\/span>)\u3002\u5c3d\u7ba1\u8fd9\u4e9b\u7ed3\u679c\u4f3c\u4e4e\u6bd4\u5355\u72ec\u4f7f\u7528\u5229\u59a5\u6614\u5355\u6297\u7684\u9884\u671f\u8981\u9ad8\uff0c\u4f46\u8054\u5408\u6cbb\u7597\u7684\u4f7f\u7528\u4f7f\u5f97\u7ed3\u679c\u7684\u89e3\u91ca\u66f4\u52a0\u590d\u6742\u3002\u5728\u5355\u836f\u6cbb\u7597\u65b9\u9762\uff0cNivolumab\u5728\u591a\u79cd\u7c7b\u578b\u7684NHL\u4e2d\u4e5f\u663e\u793a\u51fa\u6297\u80bf\u7624\u6d3b\u6027\uff0c\u5176\u4e2dFL\u548cDLBCL\u7684ORR\u5206\u522b\u4e3a40%\u548c36%\uff0c\u4e00\u4e9b\u8fbe\u5230\u5b8c\u5168\u7f13\u89e3\u7684\u60a3\u8005\u5176\u7597\u6548\u6301\u7eed\u65f6\u95f4\u8d85\u8fc712\u4e2a\u6708\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u603b\u4e4b\uff0cNHL\u5bf9PD-1\u6216CTLA-4\u6291\u5236\u7684\u654f\u611f\u6027\u4f3c\u4e4e\u4f4e\u4e8e\u970d\u5947\u91d1\u6dcb\u5df4\u7624\uff08HL\uff09\uff0c\u4f46\u76ee\u524d\u66f4\u591a\u7684\u60a3\u8005\u6b63\u5728\u53c2\u52a0\u8054\u5408\u4e0d\u540c\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\uff08ICBs\uff09\u7684\u4e34\u5e8a\u8bd5\u9a8c\u3002\u503c\u5f97\u6ce8\u610f\u7684\u4e00\u4e2a\u4f8b\u5916\u53ef\u80fd\u662fPMBCL\u4e9a\u578b\u3002PMBCL\u4e0ecHL\u5177\u6709\u76f8\u4f3c\u7684\u751f\u7269\u5b66\u7279\u5f81\uff0c\u5305\u62ec\u7531\u4e8e9p24.1\u4f4d\u70b9\u6269\u589e\u6216\u5176\u4ed6\u673a\u5236\u5bfc\u81f4\u7684PD-L1\u8fc7\u8868\u8fbe\uff0c\u8fd9\u8868\u660ePD-1\/PD-L1\u963b\u65ad\u53ef\u80fd\u5728PMBCL\u4e2d\u4e5f\u6709\u6548\u3002\u7531\u4e8e\u8be5\u75c5\u8f83\u4e3a\u7f55\u89c1\uff0c\u4e34\u5e8a\u6570\u636e\u6709\u9650\u3002\u5728\u4e00\u9879Ib\u671f\u8bd5\u9a8c\u4e2d\uff0c\u4e24\u540dPMBCL\u60a3\u8005\u5bf9Nivolumab\u8868\u73b0\u51fa\u4e34\u5e8a\u53cd\u5e94\u3002KEYNOTE-013\u8bd5\u9a8c\u4e2dPMBCL\u72ec\u7acb\u961f\u5217\u7684\u521d\u6b65\u7ed3\u679c\u663e\u793a\uff0c\u7ecf\u8fc7\u91cd\u5ea6\u9884\u5904\u7406\u7684\u60a3\u8005\u7684\u610f\u5411\u6cbb\u7597ORR\u4e3a40%\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

Pembrolizumab\u5728\u590d\u53d1\u6027PMBCL\u60a3\u8005\u4e2d\u7684\u5e94\u7528\u7ed3\u679c\uff08NCT02576990\uff09\u5c06\u6709\u52a9\u4e8e\u9610\u660ePMBCL\u5728PD-1\u963b\u65ad\u6cbb\u7597\u4e2d\u7684\u53cd\u5e94\u662f\u5426\u4e0ecHL\u76f8\u5f53\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n

38.6.2 \u591a\u53d1\u6027\u9aa8\u9ad3\u7624<\/p>\n<\/section>\n

\n
\n
\n

\u5c3d\u7ba1PD-L1\u5728\u6d46\u7ec6\u80de\u4e2d\u6709\u8868\u8fbe\uff0c\u4f46Nivolumab\u6cbb\u7597\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\uff08MM\uff09\u7684\u521d\u6b65\u7ed3\u679c\u5e76\u4e0d\u7406\u60f3\u3002\u867d\u713663%\u7684\u60a3\u8005\u75c5\u60c5\u7a33\u5b9a\uff0c\u4f46\u6ca1\u6709\u60a3\u8005\u8fbe\u5230\u5ba2\u89c2\u7f13\u89e3\u3002\u53c2\u4e0ePembrolizumab I\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u4e00\u540dMM\u60a3\u8005\u75c5\u60c5\u7a33\u5b9a\uff0c\u6301\u7eed\u65f6\u95f4\u8d85\u8fc7\u4e00\u5e74\u3002\u8fd9\u4e9b\u7ed3\u679c\u8868\u660e\uff0c\u5355\u72ec\u963b\u65adPD-1\u8f74\u53ef\u80fd\u5bf9MM\u7597\u6548\u6709\u9650\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u968f\u7740\u7814\u7a76\u7684\u6df1\u5165\uff0c\u79d1\u5b66\u5bb6\u4eec\u5bf9PD-L1\u5728\u6d46\u7ec6\u80de\u3001\u6d46\u7ec6\u80de\u6837\u6811\u7a81\u72b6\u7ec6\u80de\uff08DC\uff09\u548c\u9ad3\u6e90\u6027\u6291\u5236\u7ec6\u80de\uff08MDSC\uff09\u4e2d\u7684\u4f5c\u7528\u8d8a\u6765\u8d8a\u611f\u5174\u8da3\uff0c\u56e0\u4e3a\u8fd9\u4e9b\u7ec6\u80de\u5728MM\u7684\u53d1\u75c5\u673a\u5236\u4e2d\u626e\u6f14\u7740\u91cd\u8981\u89d2\u8272\u3002\u76ee\u524d\uff0c\u6709\u591a\u4e2a\u4e34\u5e8a\u8bd5\u9a8c\u6b63\u5728\u8bc4\u4f30\u6297PD-L1\u5355\u6297Atezolizumab\u548cDurvalumab\u5355\u72ec\u4f7f\u7528\u6216\u8054\u5408\u4f7f\u7528\u7684\u6548\u679c\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u6b64\u5916\uff0cPembrolizumab\u4e0eRevlimid\uff08\u6765\u90a3\u5ea6\u80fa\uff09\u548c\u5730\u585e\u7c73\u677e\u6216\u6cca\u9a6c\u5ea6\u80fa\u8054\u5408\u4f7f\u7528\u7684\u65b9\u6848\u4e5f\u5728\u7814\u7a76\u4e2d\uff0c\u65e9\u671f\u4e34\u5e8a\u8bd5\u9a8c\u663e\u793a\u8fd9\u4e9b\u7ec4\u5408\u7597\u6cd5\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\uff0c\u5e76\u8868\u73b0\u51fa\u4e00\u5b9a\u7684\u6f5c\u529b\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n

38.6.3 \u9ad3\u7cfb\u6076\u6027\u80bf\u7624<\/p>\n<\/section>\n

\n
\n
\n

\u4e34\u5e8a\u524d\u6570\u636e\u8868\u660e\uff0c\u9aa8\u9ad3\u589e\u751f\u5f02\u5e38\u7efc\u5408\u5f81\uff08MDS\uff09\u6216\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u53ef\u80fd\u5bf9PD-1\/PD-L1\u6216CTLA-4\u901a\u8def\u7684\u6291\u5236\u654f\u611f\u3002\u6709\u8da3\u7684\u662f\uff0c\u4e00\u4e9b\u7814\u7a76\u663e\u793a\uff0c\u66b4\u9732\u4e8e\u4f4e\u7532\u57fa\u5316\u5242\u5730\u897f\u4ed6\u6ee8\u540e\uff0cPD-L1\u548cPD-L2\u7684\u8868\u8fbe\u4f1a\u51fa\u73b0\u5242\u91cf\u4f9d\u8d56\u6027\u4e0a\u8c03\u3002\u5c3d\u7ba1\u5982\u6b64\uff0cPD-1\u6291\u5236\u5728AML\u4e2d\u7684\u6548\u679c\u4ecd\u7136\u6709\u9650\u3002\u76f8\u5173\u4e34\u5e8a\u8bd5\u9a8c\u7684\u6570\u636e\u4e3b\u8981\u4ee5\u6458\u8981\u5f62\u5f0f\u5728\u4f1a\u8bae\u4e0a\u53d1\u8868\uff0c\u7ed3\u679c\u5c1a\u4e0d\u6210\u719f\uff0c\u96be\u4ee5\u5f97\u51fa\u660e\u786e\u7ed3\u8bba\uff0c\u4f46\u521d\u6b65\u7ed3\u679c\u663e\u793a\u5728\u90e8\u5206\u60a3\u8005\u4e2d\u786e\u5b9e\u5b58\u5728\u4e00\u5b9a\u7684\u6d3b\u6027\u3002<\/p>\n

\u5728\u5f02\u57fa\u56e0\u5e72\u7ec6\u80de\u79fb\u690d\u540e\u8fdb\u884c\u7684I\/Ib\u671f\u8bd5\u9a8c\u4e2d\uff0cIpilimumab\u663e\u793a\u51fa\u4e00\u5b9a\u7684\u7597\u6548\uff0c\u5305\u62ec4\u4f8b\u9ad3\u5916AML\u60a3\u8005\u548c1\u4f8b\u7531MDS\u8f6c\u5316\u800c\u6765\u7684AML\u60a3\u8005\u8fbe\u5230\u4e86\u5b8c\u5168\u7f13\u89e3\uff08CR\uff09\u3002\u7136\u800c\uff0c\u6b63\u5982\u5728NHL\u4e2d\u89c2\u5bdf\u5230\u7684\u90a3\u6837\uff0c\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\u4f5c\u4e3a\u5355\u4e00\u836f\u7269\u5728\u9ad3\u7cfb\u6076\u6027\u80bf\u7624\u4e2d\u7684\u7597\u6548\u53ef\u80fd\u6709\u9650\u3002\u8fd9\u4e3a\u8054\u5408\u6cbb\u7597\u63d0\u4f9b\u4e86\u7406\u8bba\u4f9d\u636e\uff0c\u4ee5\u589e\u5f3aPD-1\u6216\u5176\u4ed6\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\u7684\u6297\u80bf\u7624\u548c\u514d\u75ab\u539f\u6027\u4f5c\u7528\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n

38.7 \u672a\u6765\u53d1\u5c55\u65b9\u5411<\/p>\n<\/section>\n

\n
\n
\n

30\u591a\u5e74\u6765\uff0c\u514d\u75ab\u7597\u6cd5\u4e00\u76f4\u5904\u4e8e\u8840\u6db2\u5b66\u7684\u524d\u6cbf\uff0c\u5176\u5148\u9a71\u5de5\u4f5c\u63cf\u8ff0\u4e86\u79fb\u690d\u7269\u6297\u767d\u8840\u75c5(GVL)\u6548\u5e94\u7684\u6297\u764c\u6d3b\u6027\uff0c\u4ece\u800c\u53d1\u5c55\u4e86\u540c\u79cd\u5f02\u4f53\u79fb\u690d(HSCT)\u3002\u7136\u800c\uff0c\u79fb\u690d\u7269\u6297\u5bbf\u4e3b\u75c5(GVHD)\u4ecd\u7136\u662fHSCT\u60a3\u8005\u9884\u540e\u7684\u4e3b\u8981\u969c\u788d\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u968f\u540e\uff0c\u5229\u59a5\u6614\u5355\u6297\u8bc1\u660e\u4e86\u5355\u514b\u9686\u6297\u4f53\u5355\u72ec\u4f7f\u7528\u6216\u4e0e\u6807\u51c6\u5316\u7597\u8054\u5408\u4f7f\u7528\u7684\u5353\u8d8a\u7597\u6548\uff0c\u5f7b\u5e95\u6539\u53d8\u4e86\u6211\u4eec\u6cbb\u7597\u764c\u75c7\u7684\u65b9\u5f0f\u3002\u5c3d\u7ba1\u6709\u8fd9\u6837\u7684\u6210\u529f\u6848\u4f8b\uff0c\u4f46\u51e0\u5341\u5e74\u6765\u514d\u75ab\u7cfb\u7edf\u5728\u764c\u75c7\u6cbb\u7597\u4e2d\u7684\u4f5c\u7528\u4e00\u76f4\u88ab\u4f4e\u4f30\u3002\u76f4\u5230\u6700\u8fd1\uff0c\u4eba\u4eec\u624d\u8ba4\u8bc6\u5230\u80bf\u7624\u5177\u6709\u901a\u8fc7\u6fc0\u6d3b\u8d1f\u8c03\u63a7\u901a\u8def\u6765\u6291\u5236\u6d78\u6da6\u6027T\u7ec6\u80de\u7684\u72ec\u7279\u80fd\u529b\uff0c\u8fd9\u4e00\u53d1\u73b0\u4fc3\u4f7f\u514d\u75ab\u80bf\u7624\u5b66\u9886\u57df\u524d\u6240\u672a\u6709\u5730\u6279\u51c6\u4e86\u591a\u79cd\u514d\u75ab\u8c03\u8282\u836f\u7269\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u5c3d\u7ba1\u6709\u8bb8\u591a\u79ef\u6781\u7684\u8bd5\u9a8c\u6210\u679c\uff0c\u514d\u75ab\u68c0\u67e5\u70b9\u8c03\u8282\u9886\u57df\u4ecd\u5904\u4e8e\u65e9\u671f\u53d1\u5c55\u9636\u6bb5\u3002\u867d\u7136\u6297PD-1\u5355\u6297\u5728\u6cbb\u7597\u590d\u53d1\/\u96be\u6cbb\u6027\u7ecf\u5178\u970d\u5947\u91d1\u6dcb\u5df4\u7624\uff08cHL\uff09\u65b9\u9762\u53d6\u5f97\u4e86\u7a81\u7834\u6027\u8fdb\u5c55\uff0c\u4f46\u9700\u8981\u6ce8\u610f\u7684\u662f\uff0cICBs\uff08\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\uff09\u53ea\u80fd\u63d0\u4f9b\u957f\u671f\u7684\u75be\u75c5\u63a7\u5236\u3002\u4e3a\u4e86\u8fdb\u4e00\u6b65\u6539\u5584\u60a3\u8005\u7684\u9884\u540e\uff0c\u786e\u5b9a\u6297PD-1\u6cbb\u7597\u5728cHL\u4e2d\u7684\u6700\u4f73\u4f7f\u7528\u65f6\u673a\u4ee5\u53ca\u662f\u5426\u4e0eBV\uff08Brentuximab Vedotin\uff09\u5316\u7597\u8054\u5408\u4f7f\u7528\u4ee5\u63d0\u9ad8\u7597\u6548\u662f\u81f3\u5173\u91cd\u8981\u7684\u3002<\/p>\n

\u5728\u8fd9\u4e00\u80cc\u666f\u4e0b\uff0c\u4e34\u5e8a\u8bd5\u9a8c\u6b63\u5728\u8bc4\u4f30PD-1\u963b\u65ad\u4e0e\u4e00\u7ebf\u5316\u7597\u7ed3\u5408\u7684\u6f5c\u5728\u76ca\u5904\u3002\u4f8b\u5982\uff0cKEYNOTE-204\u7814\u7a76\uff08NCT02684292\uff09\u6b63\u5728\u6bd4\u8f83\u81ea\u4f53HSCT\uff08\u9020\u8840\u5e72\u7ec6\u80de\u79fb\u690d\uff09\u540e\u590d\u53d1\u6027cHL\u60a3\u8005\u63a5\u53d7Pembrolizumab\u6216BV\u7ef4\u6301\u6cbb\u7597\u7684\u6548\u679c\uff0c\u7c7b\u4f3c\u4e8eAETHERA\u8bd5\u9a8c\u3002\u76ee\u524d\uff0c\u5728\u5176\u4ed6\u8840\u6db2\u75c5\u60a3\u8005\u4e2d\uff0cPD-1\u6216CTLA-4\u963b\u65ad\u5242\u7684\u7597\u6548\u5c1a\u4e0d\u5982\u5728cHL\u4e2d\u663e\u8457\uff0c\u8fd9\u503c\u5f97\u8fdb\u4e00\u6b65\u7814\u7a76\uff0c\u7279\u522b\u662f\u5728\u8840\u6db2\u80bf\u7624\u7684\u514d\u75ab\u80bf\u7624\u5b66\u7814\u7a76\u4e2d\u3002<\/p>\n

\u4e34\u5e8a\u524d\u6570\u636e\u8868\u660e\uff0c\u65b0\u578b\u836f\u7269\u5982\u514d\u75ab\u8c03\u8282\u836f\u7269\uff08IMIDs\uff09\u6216\u5c0f\u5206\u5b50\u6291\u5236\u5242\u53ef\u80fd\u5f71\u54cd\u514d\u75ab\u7cfb\u7edf\u7684\u7a33\u6001\uff0c\u5e76\u589e\u5f3a\u6cbb\u7597\u6548\u679c\u3002IMIDs\u6216\u4f9d\u9c81\u66ff\u5c3c\uff08Ibrutinib\uff09\u8054\u5408PD-1\u963b\u65ad\u5242\u6b63\u5728\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\uff08MM\uff09\u548c\u975e\u970d\u5947\u91d1\u6dcb\u5df4\u7624\uff08NHL\uff09\u7684\u591a\u9879\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u8fdb\u884c\u7814\u7a76\u3002\u5b9e\u9a8c\u6570\u636e\u8fd8\u4e3a5-\u963f\u624e\u80de\u82f7\u4e0ePD-1\u963b\u65ad\u5242\u7684\u8054\u5408\u4f7f\u7528\u63d0\u4f9b\u4e86\u7406\u8bba\u57fa\u7840\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u6b64\u5916\uff0c\u9488\u5bf9\u5176\u4ed6\u6291\u5236\u6027\u53d7\u4f53\u5982Lag-3\u3001TIGIT\u3001Tim-3\u6216OX40\u7684\u65b0\u578b\u5355\u514b\u9686\u6297\u4f53\u6b63\u5728\u5f00\u53d1\u4e2d\u3002\u4e3a\u4e86\u66f4\u6709\u6548\u5730\u7ed3\u5408\u764c\u7ec6\u80de\u548c\u7ec6\u80de\u6bd2\u6027T\u7ec6\u80de\uff0c\u5f00\u53d1\u4e86\u53cc\u7279\u5f02\u6027\u6297\u4f53\uff0c\u5982Blinatumomab\uff0c\u8fd9\u662fFDA\u6279\u51c6\u7528\u4e8e\u590d\u53d1\/\u96be\u6cbb\u6027\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08ALL\uff09\u7684\u9996\u4e2aBiTE\uff08\u53cc\u7279\u5f02\u6027T\u7ec6\u80de\u63a5\u5408\u5668\uff09\u3002\u5728\u5927\u91cf\u9884\u5904\u7406\u60a3\u8005\u4e2d\u5f00\u53d1\u9ad8\u6d3b\u6027\u5316\u5408\u7269\u5df2\u6210\u4e3a\u4e00\u4e2a\u4e0d\u65ad\u6269\u5c55\u7684\u9886\u57df\uff0c\u4e34\u5e8a\u524d\u6570\u636e\u4e5f\u652f\u6301\u5728\u767d\u8840\u75c5\u4e2d\u8054\u5408\u4f7f\u7528BiTE\u6297\u4f53\u548cPD-1\/PD-L1\u8f74\u963b\u65ad\u5242\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\u7136\u800c\uff0c\u6240\u6709\u6b63\u5728\u5f00\u53d1\u7684\u514d\u75ab\u80bf\u7624\u5b66\u836f\u7269\u4ecd\u9762\u4e34\u4e24\u4e2a\u5173\u952e\u6311\u6218\uff1a\u786e\u5b9a\u6700\u4f73\u7684\u6cbb\u7597\u987a\u5e8f\u548c\u65f6\u673a\uff0c\u4ee5\u53ca\u627e\u5230\u53ef\u9760\u7684\u751f\u7269\u6807\u5fd7\u7269\u6765\u9884\u6d4b\u7597\u6548\u3002\u76ee\u524d\uff0c\u591a\u9879\u4e34\u5e8a\u8bd5\u9a8c\u6b63\u5728\u62db\u52df\u60a3\u8005\uff0c\u5c06\u8fd9\u4e9b\u65b0\u578b\u5206\u5b50\u878d\u5165\u4e00\u7ebf\u6cbb\u7597\u65b9\u6848\u4e2d\u3002\u79d1\u5b66\u5bb6\u4eec\u8fd8\u5728\u6d4b\u8bd5\u65b0\u7684\u751f\u7269\u6807\u5fd7\u7269\uff08\u5982\u514d\u75ab\u7ec4\u5316\u3001\u57fa\u56e0\u7a81\u53d8\u548c\u80a0\u9053\u5fae\u751f\u7269\u7fa4\uff09\uff0c\u4ee5\u66f4\u597d\u5730\u9884\u6d4b\u6cbb\u7597\u53cd\u5e94\u548c\u6bd2\u6027\u3002<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n
\n

\u672c\u6587\u7531Oncolab\u5fae\u4fe1\u516c\u4f17\u53f7\u7ffb\u8bd1\u6574\u7406\u81eaOncoimmunology: A Practical Guide for Cancer Immunotherapy\uff0c\u4ec5\u7528\u4e8e\u5b66\u4e60\u4ea4\u6d41\u4f7f\u7528\uff0c\u5982\u9700\u8d2d\u4e70\u539f\u7248\u4e66\u7c4d\u53ef\u70b9\u51fb\u9605\u8bfb\u539f\u6587\u8d2d\u4e70\u3002<\/span>
<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n

\u2014 THE  END \u2014<\/span><\/p>\n


<\/p>\n

\u6765\u6e90 | Oncoimmunology: A Practical Guide <\/span><\/p>\n

for Cancer Immunotherapy<\/span><\/p>\n

\u521d\u7a3f\u7ffb\u8bd1 | \u7f57\u8377<\/span><\/p>\n

\u56fe\u6587\u6392\u7248 | \u90ed\u5b50 \u5e94\u6b63<\/span><\/span><\/p>\n

\u5ba1\u6838\u4fee\u6539 | \u738b\u5764<\/span><\/p>\n

\uff08\u8f6c\u8f7d\u8bf7\u4fdd\u7559\u6b64\u90e8\u5206\u5185\u5bb9\uff09<\/span><\/strong><\/p>\n


<\/p>\n


<\/p>\n

\u2589  \u5f80\u671f\u63a8\u9001\u5408\u8f91<\/strong><\/strong><\/section>\n
\n
\n
\n
\n
<\/strong><\/strong><\/section>\n<\/section>\n<\/section>\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n

\u80bf\u7624\u514d\u75ab\u5b66\u6700\u65b0\u6587\u732e<\/span><\/a>
<\/p>\n

\u53ef\u4ee5\u67e5\u8be22024\u5e74\u6700\u65b0SCI\u671f\u520a\u5f71\u54cd\u56e0\u5b50\u53ca\u5206\u533a\u5566\uff01<\/span><\/a>
\u514d\u75ab\u5b66\u62fe\u9057\u7cfb\u5217<\/span><\/a><\/p>\n

\u80bf\u7624\u514d\u75ab\u5b66\u7cfb\u5217<\/span><\/a><\/p>\n

\u795e\u7ecf\u79d1\u5b66\u539f\u7406\u7cfb\u5217<\/span><\/a><\/p>\n

ACIR\u6587\u732e\u901f\u9012<\/span><\/a><\/p>\n

SCI\u8bba\u6587\u4f5c\u56fe<\/span><\/a><\/p>\n

SCI\u8bba\u6587\u5199\u4f5c\u53ca\u6295\u7a3f<\/span><\/a><\/p>\n

\u751f\u4fe1\u5165\u95e8\u5b66\u4e60\u7b14\u8bb0<\/span><\/a><\/p>\n

R\u8bed\u8a00\u57fa\u7840\u4e0e\u5355\u7ec6\u80de\u5206\u6790\u5b9e\u6218\u89c6\u9891\u8bfe\u7a0b<\/span><\/a><\/p>\n

\u751f\u7269\u5b66\u5b9e\u9a8c\u6280\u672f\u53ca\u5e38\u7528\u8f6f\u4ef6<\/span><\/a><\/p>\n

\u5e38\u7528\u5b9e\u9a8c<\/span>\u4eea\u5668\u7b80\u4ecb\u53ca\u64cd\u4f5c\u89c6\u9891<\/span><\/a><\/span><\/p>\n

\u5e38\u7528\u7535\u8111\u8f6f\u4ef6\u4f7f\u7528\u6559\u7a0b<\/span><\/a><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n
\n


<\/p>\n

<\/span><\/p>\n

\u5173\u6ce8\u672c\u53f7~<\/span>
<\/p>\n


<\/p>\n

<\/p>\n

\u52a0\u5165\u8bfb\u8005\u4ea4\u6d41\u7fa4~<\/span><\/p>\n

\uff08\u6dfb\u52a0\u8bf7\u5907\u6ce8\u5355\u4f4d\u59d3\u540d\uff09<\/span><\/p>\n


<\/p>\n

<\/p>\n

\u52a0\u5165\u77e5\u8bc6\u661f\u7403~<\/span><\/p>\n


<\/p>\n


<\/p>\n


<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\u70b9\u4eae\u8d5e\u4e0e\u5728\u770b <\/span><\/p>\n

\u8ba9\u66f4\u591a\u4eba\u770b\u5230<\/span><\/p>\n

<\/mp-style-type><\/p>\n

\n

\u672c\u7bc7\u6587\u7ae0\u6765\u6e90\u4e8e\u5fae\u4fe1\u516c\u4f17\u53f7: OncoLab <\/p>\n<\/blockquote>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u4e0a\u671f\u5185\u5bb9\uff1a\u80bf\u7624\u514d\u75ab\u5b66-\u7b2c38\u7ae0 \u8840\u6db2\u80bf\u7624\u514d\u75ab\u80bf\u7624\u5b66\u7814\u7a76\u73b0\u72b6\uff08\u4e0a\uff09 38.3 \u535a\u7eb3\u5410\u5355\u6297:\u590d\u53d1\/\u96be\u6cbb\u6027ALL\u7684\u65b0…<\/p>\n","protected":false},"author":1,"featured_media":3697,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[65],"tags":[],"_links":{"self":[{"href":"http:\/\/oncolab.cn\/index.php\/wp-json\/wp\/v2\/posts\/3699"}],"collection":[{"href":"http:\/\/oncolab.cn\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/oncolab.cn\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/oncolab.cn\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/oncolab.cn\/index.php\/wp-json\/wp\/v2\/comments?post=3699"}],"version-history":[{"count":0,"href":"http:\/\/oncolab.cn\/index.php\/wp-json\/wp\/v2\/posts\/3699\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/oncolab.cn\/index.php\/wp-json\/wp\/v2\/media\/3697"}],"wp:attachment":[{"href":"http:\/\/oncolab.cn\/index.php\/wp-json\/wp\/v2\/media?parent=3699"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/oncolab.cn\/index.php\/wp-json\/wp\/v2\/categories?post=3699"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/oncolab.cn\/index.php\/wp-json\/wp\/v2\/tags?post=3699"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}